IP Library Granted Patent US 8,067,597
Granted Patent B2
US 8,067,597 · App. 11/917,180 · Granted Nov 29, 2011

Synthetic route to 14-hydroxyl opiates through 1-halo-thebaine or analogs

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,067,597
App. No.
11/917,180
Granted
Nov 29, 2011
Kind
B2
Abstract

Novel methods of synthesis of known and novel 14-hydroxyl opiates through 1-halothebaine and derivatives are described.

Claims (28)

1. A one-pot process for the conversion of a compound according to Formula 14 into a compound according to Formula 17, the process comprising:

a) heating the compound according to formula 14 in the presence of at least one acid to form a compound according to formula 15;

b) oxidizing the compound according to Formula 15 with at least one oxidizing agent to form a compound according to Formula 16; and

c) reducing the compound according to Formula 16 with at least one reductive agent to form a compound according to Formula 17;

wherein R 1 is H, methyl, a benzyl group, an aryl group, an acyl group, an alkoxycarbonyl group or tetrahydropyranyl group;

R 2 is H, methyl, a benzyl group, an aryl group, an acyl group, a formyl group, a formyl ester, an alkoxycarbonyl group or alkylamidocarbonyl group;

R 3 is H, an alkyl group, an aryl group or an acyl group; and,

X is a halogen.

2. The process of claim 1 , wherein the process is for the preparation of compounds according to Formula 17, the process additionally comprising:

a) catalytically converting a compound according to Formula 9 into a compound according to Formula 10 in the presence of at least one catalyst, wherein the catalyst is at least one transition metal complex of the formula [M(PR 4 R 5 R 6 ) n X m ] p ; wherein M is a Group VIII transition metal; R 4 , R 5 and R 6 are selected from the group consisting of alkyl, aryl, alkoxyl, phenoxyl and combinations thereof; X is a halide or an anion; n is 1, 2, 3 or 4; m is 1 or 2; and p is at least 1;

b) halogenating the compound according to Formula 10 with at least one halogenating reagent in at least one protic solvent in the presence of R 7 C(OR 3 ) 3 , wherein R 7 is H, an alkyl or an alkoxy, and at least one first acid to form a compound according to Formula 13;

c) reacting the compound according to Formula 13 with less than about two equivalents of at least one base to form a compound according to Formula 14; and

d) heating the compound according to formula 14 in the presence of at least one second acid to from a compound according to Formula 15.

3. The process of claim 2 wherein the at least one first acid includes an acid selected from the group consisting of sulfuric acid (H 2 SO 4 ), phosphoric acid (H 3 PO 4 ), methanesulfonic acid (MeSO 3 H), p-toluenesulfonic acid, trifluoroacetic acid, trifluoromethanesulfonic acid, hydrogen chloride (HCl), hydrogen bromide (HBr) and mixtures thereof;

the at least one halogenating reagent includes a halogenating reagent selected from the group consisting of bromine (Br 2 ), N-bromoacetamide (NBA), N-bromosuccinimide (NBS), 1,3-dibromo-5,5-dimethylhydantoin (DBDMH), 1,3-dichloro-5,5-dimethylhydantoin (DCDMH), N-chlorosuccinimide (NCS) and mixtures thereof;

the at least one second acid includes an acid selected from the group consisting of HOAc, HCO 2 H, RCO 2 H wherein R is an alkyl, benzyl or aryl, MeSO 3 H, p-toluenesulfonic acid, CF 3 CO 2 , POCl 3 and mixtures thereof;

the at least one oxidizing agent includes an oxidizing agent selected from the group consisting of hydrogen peroxide solution, peroxyacetic acid, 3-chloroperoxybenzoic acid, RCO 3 H wherein R is H, an alkyl, or an aryl, and mixtures thereof; and

the at least one reductive agent includes a reductive agent selected from the group consisting of a combination of pressurized hydrogen on metal supported catalyst having the formula M/C, wherein M is Pd, Pt, Ru, or Rh and C is carbon.

4. The process of claim 1 , wherein:

R 1 is H, CH 3 , PhCH 2 , R 8 CO, R 8 OCO or a tetrahydropyranyl group;

R 2 is H, CH 3 , PhCH 2 , CHO, R 8 CO or R 8 OCO;

R 8 is C 1-6 alkyl;

R 3 is C 1-4 alkyl or acetate; and

X is Cl or Br.

5. The process of claim 1 wherein the at least one oxidizing agent includes an oxidizing agent that is selected from the group consisting of hydrogen peroxide solution, peroxyacetic acid, 3-chloroperoxybenzoic acid, RCO 3 H wherein R is H, and alkyl, or an aryl, and mixtures thereof.

6. The process of claim 1 , wherein in step (b), R 3 in R 7 C(OR 3 ) 3 is Me.

7. The process of claim 6 , wherein R 1 and R 2 are methyl and X is Br.

8. The process of claim 2 , wherein the at least one reductive agent includes a reductive agent selected from the group consisting of a combination of pressurized hydrogen on metal supported catalyst having the formula M/C, wherein M is Pd, Pt, Ru, or Rh and C is carbon.

Assignments (14)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
CHANGE OF LEGAL ENTITY Recorded Aug 16, 2011
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 026754/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2007
From: WANG, PETER X.; MOSER, FRANK W.; CANTRELL, GARY L.; MAGPARANGALAN, DANIEL P.; BAO, JIAN
To: MALLINCKRODT INC.
Reel/Frame 020226/0308 →